<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840527</url>
  </required_header>
  <id_info>
    <org_study_id>12-488</org_study_id>
    <nct_id>NCT01840527</nct_id>
  </id_info>
  <brief_title>Utility of Novel BRAF Test for Melanoma</brief_title>
  <official_title>Exploring the Utility of a Novel BRAF Test in Patients With Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This primary purpose of this study is to obtain blood samples from participants with both&#xD;
      early and later stages of melanoma (Stage II/III and Stage IV). The researchers hope to&#xD;
      better understand an abnormal protein found in many melanoma tumors called the BRAFV600&#xD;
      mutation.&#xD;
&#xD;
      There will be two separate cohorts (groups) of participants on this study. You will be placed&#xD;
      in one of the Groups.&#xD;
&#xD;
      Group 1-For participants with advanced melanoma: Your existing tumor tissue sample will be&#xD;
      compared to the blood samples given in order to further analyze and to understand the&#xD;
      BRAFV600E gene mutation.&#xD;
&#xD;
      Group 2-For participants with stage II/III melanoma: Following surgery, blood samples will be&#xD;
      collected and analyzed.&#xD;
&#xD;
      Understanding the BRAFV600E gene mutation in melanoma will help the researchers better&#xD;
      understand the disease, and help plan treatment options for people with melanoma of all&#xD;
      stages in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be no extra clinic visits for this study. These research blood samples will be&#xD;
      drawn at the same time as your regularly scheduled blood draws that are part of standard care&#xD;
      for melanoma.&#xD;
&#xD;
      About 2 to 4 teaspoons of blood will be drawn for each research sample.&#xD;
&#xD;
      Depending on which group you are in, you will have either a one time blood draw or ongoing&#xD;
      blood work for 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Actual">March 29, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Specificity and Sensitivity of Blood Based Assay</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the specificity and sensitivity of the blood based assay vis-a-vis tissue based BRAF analysis in patients with advanced and high-risk melanoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore Pharmacodynamic Effects of MAPK Pathway Inhibitors</measure>
    <time_frame>2 years</time_frame>
    <description>To explore the pharmacodynamic effects of MAPK pathway inhibitors (including selective BRAF inhibitors, MEK inhibitors, and ERK inhibitors) utilizing pre-and on-treatment peripheral blood BRAFV600E mutational testing in patients with advanced melanoma, (non-resectable Stage III or Stage IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define Prognostic Value of Peripheral Blood BRAFV600 Testing in Melanoma</measure>
    <time_frame>2 years</time_frame>
    <description>To define the prognostic value of peripheral blood BRAFV600 mutational testing in patients with Stage II and resectable Stage III melanoma</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">220</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Advanced Melanoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Stage II/III Melanoma</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood lymphocytes (PBLs); Plasma; Tumor Tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients being treated at Massachusetts General Hospital, Dana-Farber Cancer Institute and&#xD;
        Beth Isreal Deaconess Medical Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven advanced (unresectable stage IIIC or stage IV)or high risk (stage II or&#xD;
             stage III) malignant melanoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of a different malignancy except for the following circumstances: disease-free&#xD;
             for at least 2 years and deemed by the investigator to be at low risk for recurrence;&#xD;
             or non-metastatic prostate cancer, cervical cancer in situ and basal cell or squamous&#xD;
             cell carcinoma&#xD;
&#xD;
          -  Known history of a different BRAF mutant malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ryan Sullivan, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Biomarker</keyword>
  <keyword>BRAF</keyword>
  <keyword>blood-based</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

